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Abstract 
Multidrug-resistant organisms (MDRO) pose a great threat to health across the globe.  That 
threat is also felt in the Veterans Health Administration (VHA).  Wounded warriors returning 
home from the battlefields of Iraq and Afghanistan may have brought with them MDROs, such 
as the bacterium Acinetobacter baumannii, as they have transitioned from military service into 
the VHA facilities.  This study investigates the interconnectedness of military service in the 
Department of Defense (DoD) and a lifetime of care at VHA through a longitudinal tracking of a 
linked cohort of combat veterans with battlefield injuries and subsequent MDR infections of A. 
baumannii.  This study has sought to understand the spread of this MDRO beyond returned 
combat veterans as a potential reservoir to others throughout the nationwide VA healthcare 
system.  This study will highlight the downstream implications of emerging MDROs brought 
back home from future foreign wars and campaigns that U.S. Armed Forces become engaged in.  
Furthermore, it will underscore the need for modernization of the current MDRO identification 
and surveillance capabilities of VHA to adopt more utility of available molecular techniques.  
With appropriate pathogen identification and surveillance, this knowledge can have a significant 
impact on infection prevention and control programs, antibiotic stewardship plans and drug 
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Chapter 1 – Introduction 
 
Research Question 
Multidrug-resistant organisms (MDRO) have long been recognized as a tremendous global threat 
as they show more and more resistance to commonly used antibiotics used to treat common 
infections [3].  Many experts have warned of what is referred to as the post-antibiotic era, in 
which the drugs that we have relied upon for decades will become less reliable and even 
completely ineffective at treating and managing bacterial infections due to drug resistance. 
The Veterans Health Administration (VHA), the healthcare arm of the Department of Veterans 
Affairs (VA), is the largest integrated healthcare system in the United States of America serving 
9 million military veterans in all 50 states and territories.  VHA hospitals and clinics lie 
downstream from those in the Department of Defense (DoD) as military personnel transition 
from military service to civilian service in VA. This study examined the relationship of incidence 
of carbapenem-resistant Acinetobacter baumannii (CRAb) infections, an MDRO, from the 
increase in enrollments of military veterans with a combat deployment to either Iraq or 
Afghanistan in support of Operation Iraqi Freedom (OIF) or Operation Enduring Freedom (OEF), 
respectively.   
Specific Aims 
This study has sought to demonstrate the interconnected nature of the relationship between 
DoD and VHA by showing increased incidence rate in the number of CRAb infections across VHA 
associated with returning wounded warriors from the battlefields of Iraq and Afghanistan as a 
possible reservoir and their subsequent enrollment in VHA.  While this DoD-VA connection of 
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disease exposure has been inferred in an upstream to downstream relationship, it has not ever 
been demonstrated across the entire VA healthcare system using VA data[4, 5].   
The DoD has invested a great deal of resources into the molecular identification and 
surveillance of MDROs within its population across the organization.  This information is 
available to military physicians and other professionals through electronic databases and other 
partnerships [4-7].  However, across its 153 medical centers and hospitals, VHA does not 
currently utilize advanced molecular methods of identification or surveillance for MDROs or 
underutilizes existing molecular techniques such as polymerase chain reaction (PCR) [8]. This 
makes it challenging for physicians to know exactly which pathogen they are initially faced with 
as they treat their patients.  Modernization of laboratory pathogen identification practices 
using molecular techniques such as quantitative polymerase chain reaction (qPCR), pulsed field 
gel electrophoresis (PFGE), ribotyping and whole genome sequencing (WGS) would allow for 
adequate identification and molecular surveillance of MDROs to be conducted across the entire 
across the organization [9]. 
Significance 
The findings of this study demonstrate the interconnectedness of the DoD and VA and the 
downstream implications for infectious diseases with such a relationship.  These implications 
will have impacts on drug formularies used in treatment of infections, antibiotic stewardship 
plans, and infection control policies at both the local and national level.  Furthermore, this 
study has underscored the importance of adopting molecular microbial identification and 
surveillance practices that will prevent the spread of MDROs for existing veteran patients and 
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improve the transition of wounded warriors to VA health care and their treatment outcomes 
while at VHA. 
Chapter 2 – Background  
 
Description of the Health Problem 
The two major conflicts that the Unites States has most recently been engaged in are Operation 
Enduring Freedom (Greater 
Southwestern Asia, the Philippines, 
and North Africa) and Operation 
Iraqi Freedom (Greater Middle 
East) as seen in Figure 1.  Many 
military personnel would serve 
multiple combat tours in one or 
both theaters of operation.  The 
nature of combat in these two 
conflicts have been conventional as 
has been the case in many previous 
wars, but one distinctive characteristic about these two wars are the enemy’s use of improvised 
explosive devices (IEDs) or roadside bombs detonated remotely when U.S. forces are in 
proximity to the device.  These explosive devices have caused a great deal of casualties across 
the two battlefields.  Casualty rates show an increase in the comparison of wounded casualties 
to fatalities compared to previous U.S. conflicts in Vietnam and the Persian Gulf. Mortality rates 
 
Figure 1.  Map of Operation Enduring Freedom and Operation 
Iraqi Freedom as of December 2008.  Source: [2] 
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are relatively low considering the length of both campaigns and the technicalities of combat 
across these two theaters [10].  However, combat lifesaving first aid and advances in battlefield 
medicine and body armor have resulted in many wounded warriors returning from these 
battlefields with a variety of injuries resulting in increased survivability [7, 11]. 
Battlefield triage takes place within combat zones, especially regarding trauma cases resulting 
from combat injuries.  These levels are defined in Table 1.  Many wounded warriors requiring 
medical evacuation (MEDEVAC) have sustained significant bone and soft tissue damage and due 
to the nature of combat injuries, widespread wound contamination, which make up care levels 
IV and V.  This made infection control along MEDEVAC pathways difficult to manage [4, 5]. 
Table 1.  Trauma Care Levels Within Combat Zones  
Level Definition 
I Point of injury/first responder care  
II Resuscitation and surgical stabilization at medical units  
III Medical/surgical care at combat support or other theater hospitals 
IV Evacuation to regional medical center location (Landstuhl Regional Medical Center, Germany) 
V Definitive treatment/rehabilitation at major tertiary care medical centers in United States 
 
34% of combat casualties that were medically evacuated from the combat zone were diagnosed 
with an infection during their hospital stay.  20% involved skin and soft tissue infection (SSTI) 
and another 6% were osteomyelitis [12].  Epidemiology studies of war infections suggest that 
the majority of those evacuated under Level IV and V trauma are due to Gram negative bacteria 
species, including A. baumannii [13, 14].  However, while A. baumannii has represented a 
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significant burden of the battlefield infection complications among wounded casualties, A. 
baumannii is not captured in ICD-9 codes within the JTTR and therefore underrepresented in 
clinical significance studies [11].  Complications from battlefield injuries, such as combat-related 
infections, can persist long after departure from military service and into civilian life where this 
study focuses [5]. 
 
Scientific Background 
Acinetobacter baumannii is a gram-negative coccobacillus bacterial organism with a well-known 
reputation as an opportunistic nosocomial pathogen due to its environmental resilience by 
avoidance to desiccation on fomites, contaminating hospital environments, and its multidrug-
resistant profile [7, 14-20].  Although not a particularly virulent wild type organism (in its 
natural state), when put under constant stress conditions, such as antimicrobial pressure, it can 
manifest its ability to be very problematic for hospitals for this is how this organism can shift in 
its expressed phenotype from being sensitive to antimicrobial drugs to a resistance of 
antimicrobial drugs [16, 21].  Not only is this organism a threat to patients, but staff alike.  One 
such documented case demonstrated an occupational transmission of this organism from an 
infected patient to healthcare worker [22].   A. baumannii is known to possess a rather large 
resistome, which is the collection of genes that enable antibiotic resistance and that give this 
organism its competitive edge against treatment drugs [23].  This bacterium is unique in that it 
has acquired an ability to demonstrate resistance to 
carbapenem antibiotics, a class of beta-lactam 
antibiotics active against many Gram-positive and 
 
Figure 2 – Mechanism of activity among 




Gram-negative organisms; these drugs are usually reserved for the most resistant infections 
which this study has focused on [3, 24].  A. baumannii also belongs to another class of 
concerning pathogens, namely the ESKAPE pathogens.  The ESKAPE pathogens are a group of 
bacteria (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 
baumannii, Pseudomonas aeruginosa, and Enterobacter Sp.) that present difficult-to-treat 
options for physicians due to acquired resistance genes, the increase in disease burden and 
increased mortality rates due to treatment complications and demand a coordinated global 
response for surveillance of antimicrobial resistance[21].   
Carbapenem-resistant Acinetobacter baumannii (CRAb) include a highly problematic class of 
MDROs, namely the carbapenemase-producing organisms (CPO).  There are many mechanisms 
resulting in the CRAb phenotype: namely efflux pumps, pathogenic gene islands within its 
genome, which promote horizontal gene transfer through the use of plasmids and include 
carbapenem-hydrolyzing oxacillinase-encoding genes 
(Oxa23-like, Oxa24-like, Oxa51-like, Oxa58-like), other 
beta-lactamase enzymes, the ability to make 
adjustments to outer membrane proteins such as 
penicillin binding proteins, or make adjustments to 
metabolic pathways (porins)  and the ability to produce 
biofilms [16, 21, 25-28].  Plasmids are of particular 
concern for spreading antimicrobial resistance because 
contained within plasmids are integrons.  A. baumannii contains both class I and class II 
integrons which have been strongly associated with antibiotic resistance and the spread of 
 
Figure 3 – Electron Micrograph of a biofilm 
Acinetobacter baumannii on collagen 
substrate 
Source:  Bone and Joint Research Lab, University of Utah[1] 
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resistance in healthcare settings from contact with other bacteria in the hospital environment 
such as Enterobacteriaceae or Pseudomonas species.  The most notable example of integron 
transfer between species of bacteria is that of Pseudomonas and A. baumannii with the 
attainment of the class I integron which contains blaVEB-1 extended-spectrum β-lactamase 
(ESBL) and six other antimicrobial resistance genes, obtained from P. aeruginosa [14, 20].  
One study, examining carbapenem-resistant Gram-negative organisms, discovered that among 
CPOs, the carbapenem resistance rate in A. baumannii was 40.1% in blood samples, 50.4% in 
respiratory samples, 42% in urine samples, and 42% in other types of samples [29]. Morbidity is 
also impacted as those patients with carbapenem-resistant (CR) infections had much longer 
length-of-stay in both general medical and intensive care wards.  The crude odds ratio for 
hospitalization mortality comparing (CR) vs. carbapenem-sensitive (CS) organisms were 1.31 for 
Escherichia coli isolated from respiratory samples to 3.91 for A. baumannii isolated from blood 
samples.  Overall, patients with CR infections had longer hospital stays, more antibiotic drug 
treatment, higher mortality rates and higher economic burden to the hospital than those with 
CS infections [29].   
In 2019, the Centers for Disease Control and 
Prevention (CDC) has reclassified CRAb from 
a serious threat in its last report in 2013, to 
an urgent threat, the most perilous 
classification in its threat assessment matrix. 
CRAb has been responsible for approximately 
 
Figure 4 – CDC assessment of CRAb and its impact to 
morbidity, mortality, and economic burden. 




8,500 hospitalizations, 700 deaths and healthcare costs totaling $281M in the United States 
alone in 2017[3].  
Risk factors for MDRO infections include chronic obstructive pulmonary disease (COPD), 
diabetes mellitus, renal disease, excessive alcohol consumption, smoking and other 
immunocompromising conditions such as cancer and organ transplants [24].  This is of 
particular concern for the population of VHA, where its members are disproportionately older 
in age and exhibit more comorbidities than the general population [30]. For example, 
prevalence of diabetes mellitus in the VHA population is 25%, while the general population is 
approximately 13% [30, 31].  Furthermore, due to the occupational hazards and unique 
exposures of military service, such as burn pits or radiation exposure, healthcare delivery 
among the veteran population is very unique [32].  High prevalence of risk factors such as these 
in VHA makes management and treatment of bacterial infections challenging, let alone the 
treatment of MDROs [26].  
While infection cases of A. baumannii in the United States are not uncommon, multidrug-
resistant strains of A. baumannii infection cases in the United States, once rare, are on the rise 
[3, 15].  CRAb was not observed in the VA on a large scale until wounded warriors began 
integrating into VA hospitals and clinics from the OEF/OIF battlefields they were casualties on 
while in military service [33].   
The DoD has invested a great deal of resources into molecular technologies (such as whole 
genome sequencing) in the identification and surveillance of CRAb and other MDROs, which 
have originated from Operation Enduring Freedom (Afghanistan)/Operation Iraqi Freedom 
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(Iraq) (OEF/OIF) battlefields [4, 5, 7, 14, 34].  DoD healthcare and research laboratories have 
been able to identify and track patient samples using these molecular techniques [6].  
Unfortunately, the VA does not have this level of molecular granularity in its in-house 
laboratory practices for routine surveillance purposes and therefore the identification of clonal 
outbreaks of CRAb and other MDROs can be challenging [6, 8].   
Furthermore, because CRAb from OEF/OIF battlefields has a much different antibiotic 
resistance profile from other A. baumannii strains encountered in the United States, the 
implications on the effectiveness of the current drug formulary used by VA physicians and 
pharmacies are significant [6, 35]. With advanced knowledge, using proposed laboratory 
pathogen identification practices as an outcome recommendation of this study, improvements 
to the facility level or national level Antibiotic Stewardship plan could be applied and 
appropriate drugs or combination of drugs to produce favorable treatment outcomes will be 
possible [9]. But currently, VA physicians and pharmacists do not have comprehensive 
information to design the appropriate treatment plan that will produce the most favorable 
outcomes as possible and mitigate the spread of MDROs.    
Limitations and gaps in existing literature 
Previous studies [4, 5] assessing the long-term impact of battlefield injuries have only 
considered complications from battlefield trauma but have not considered the impact of a 
foreign MDROs such as CRAb to an entire hospital system with a vulnerable population.  This 
study has assessed the risk this exposure will have on not just one medical center, but across 
the entire organization.  
14 
 
Chapter 3 – Data and Methods 
 
Study design 
This study was designed as a retrospective case control study relating the migration of CRAb 
from DoD battlefields to VHA facilities. It was hypothesized that the prevalence of CRAb in VHA 
has been relatively low prior to the recent conflicts in Iraq and Afghanistan.   It was further 
hypothesized that due to the influx of enrolled combat veterans in VHA, particularly after the 
troop surge of 2007, that incidence rates of CRAb cases would increase significantly across the 
organization.  Comparing the number of CRAb cases to the number of enrolled OEF/OIF 
veterans that have entered VHA should show significant correlation.  Counts of carbapenem 
resistant Acinetobacter baumannii (CRAb) infections among hospitalized patients was tracked 
each year for purposes of incidence monitoring in the VA population nationwide.  Inclusion of 
A. baumannii  that did not fit the operational definition for CRAb was included as well for 
comparison purposes as screening/identification for MDROs such as CRAb was not consistent 
across VHA [8].  As a result, there may be some cases of CRAb that are underrepresented in 
VHA. 
Data Sources and Measurement  
The VHA has been a pioneer in the electronic health record, with structured medical data 
available nationwide as early as 1999.  VHA stores patient-level data in a hierarchical health 
information system called Veterans Health Information Systems and Technology Architecture 
(VistA).  This information is made available to authorized data users through access to the VA 
Corporate Data Warehouse (CDW) and VA Informatics and Computing Infrastructure (VINCI), 
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which is a high-performance computing environment that provides research teams with a 
secure and central location for data access and application development.  The CDW is used 
throughout the entire healthcare system and therefore can be used to survey patient records 
using Microsoft Structured Query Language (SQL) programming in a relational database 
environment.  Adding to these capabilities is a data source known as DoD and VA Infrastructure 
for Clinical Intelligence (DAVINCI), which uses the Observational Medical Outcomes Partnership 
(OMOP) and Common Data Model (CDM).  Using a common patient identifier and primary key 
across both data sources will allow for identification of those patients who sustained battlefield 
injuries while in active-military status and allow for further observation of this cohort as they 
move within the VA system. 
Data collection for this project was completed under a study protocol approved by the 
University of Utah School of Medicine, Department of Internal Medicine Institutional Review 
Board (IRB) for use in the Veterans Health Administration.  Data extraction for this project was 
performed in Microsoft SQL Server Management Studio 18 (Microsoft Redmond, WA). 
 
Setting and study population 
During the early stages of the OEF/OIF conflicts, the incidence of Acinetobacter spp. was noted 
among casualties and among environmental samples of MTFs across the two battlefield 
theaters [7]. This study examined a sample of cases from the DoD in which battlefield injuries 
were or were not sustained on OEF/OIF battlefields from 2008-2012* resulting subsequent 
infections from A. baumannii and CRAb.  Battlefield injury status was indicated by a flag within 
the DAVINCI database.    This group of OEF/OIF combat soldiers would be followed into VHA to 
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see if incidence of CRAb would increase across the organization.  Another sample of controls 
consisted of OEF/OIF era Veterans that did not deploy to OEF/OIF battlefields.   
*Note:  There is a limitation of the DAVINCI data source in that battle injury and clinical 
microbiology laboratory data are only available from 2008 forward.  As a result, analysis of data 
from earlier in the two conflicts (2003-2007) were not available. 
Within VHA, nationwide cohort of combat veterans was retrospectively created from the period 
2003 through 2010 who served in either OEF or OIF.  Another retrospective cohort of patients 
was created along the same period, who did not have a deployment to Iraq or Afghanistan.  
These combat deployments were identified by a flag and record of presence or absence of 
combat dates within the CDW.   All patients were hospitalized with microbiology cultures 
identifying  A. baumannii or CRAb. 
A somewhat related, but more in-depth longitudinal study conducted by Tribble et al. [21,22] 
examined a cohort of battlefield injuries in what is known as the Trauma Infectious Disease 
Outcomes Study (TIDOS).  The TIDOS cohort was studied to evaluate both short and long-term 
infectious complications for those who sustained deployment-related injuries from Operation 
Enduring Freedom and Operation Iraqi Freedom combat theaters.  Utilizing this same cohort is 
not feasible for the scope of this project, as the cohort was limited to only one VA medical 
center.  For the purposes of this study, a nationwide cohort of enrolled Veterans Affairs 





Table 2.  Variables of Consideration  
Outcome Exposure 
DoD CRAb Sustained battlefield injury 
DoD Ab Sustained battlefield injury 
VHA CRAb OEF/OIF Era Veteran 
VHA Ab OEF/OIF Era Veteran 
OEFOIF CRAb OEF/OIF Combat Deployment 
OEFOIF Ab OEF/OIF Combat Deployment 
 
Operational Definitions 
VHA defines a multi-drug resistant organism (MDRO) as: “microbes able to withstand the killing 
or inhibitory effect of several different antimicrobial agents.  The exact number and types of 
antimicrobial classes to which a microorganism is resistant varies depending on the pathogen 
“[36]. 
 
Table 3. Detailed Pathogen Phenotype Definition  









Any isolate with at least 
1 non-susceptible result 
(I or R) to: imipenem, 
meropenem, doripenem 
Any isolate with 
at least 1 
susceptible (S) or 
non-susceptible 
result (I, R) to at 
least 1 drug in the 
medications 
category 




Any isolate with at least 
1 susceptible result (I or 
Any isolate with 





doripenem R) to imipenem, 
meropenem, doripenem 
susceptible result 
(I, R) to at least 1 






Incidence rates of CRAb were calculated amongst the combat Veteran cohort as well as those 
who do not have a history of recent combat (with and without exposure).   
Incidence rate ratios were calculated among DoD personnel with battlefield injuries, among 
VHA OEF/OIF era Veteran patients and among OEF/OIF era Veteran patients with a combat 
deployment to OEF or OIF battlefields to assess the risks of these exposures.  Subsequent trend 
analyses were performed for CRAb in each group with their respective exposures. 
Statistical Analysis   
Statistical analyses among DoD and VA populations were performed by using a non-parametric, 
chi-square test to trend infection cases over time.  Incidence rates and incidence rate ratios 
were calculated from summary data.  Significance level at P <0.05 was set for these analyses.  






Chapter 4 – Results 
 
Study population  
The study population for this study involved both personnel from the Department of Defense and 
the Veterans Health Administration.  In VHA, Veterans are classified by the era of conflict in 
which they served under; some veterans can be classified under multiple eras, such as WWII, 
Korea and Vietnam.  Serving under a particular era does not necessarily mean that a veteran 
served in a combat zone; combat zone designations are indicated by the Department of Defense 
and Congress.  To be considered as having served in a combat deployment, a military member 
will be temporarily assigned to serve a tour of duty in one of these locations for a designated 
amount of time.  This is what is meant by a combat deployment to a battlefield theater.   
In VHA, these conflict eras span from World War II era until the present day which is considered 
the Gulf War era.  The Gulf War era is subdivided by those Veterans that served in the Persian 
Gulf War (1990-1991)  as well as to the present time which includes Operation Enduring 





Figure 5.  Study population of DoD and VHA  
Descriptive data  
The distribution of troop levels in both combat theaters over time in Figure 6 show that most of 





Figure 6.  Number of military personnel in Iraq and Afghanistan from FY2002-2012* 
*Data from Congressional Research Service, DoD – Joint Chiefs of Staff, “Boots on the 
Ground Reports” [2] 
 
Total enrollments in VA services shown in Figure 6 indicate that during the years that demand 
for resources in the form of personnel during the OEF/OIF conflicts were ongoing, there is an 
apparent drop in the number of veterans enrolling in VA health services.  However, after the 





































Figure 7.  Total enrollments in VHA from CY2003-2010 across all eras. 
 
Among the most active enrollments were the OEF/OIF veterans enrolling in VA services from 
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Figure 8.  Enrollments in VHA among OEF/OIF Veterans CY2003-2012 
 
Among OEF/OIF era veterans considered for this study, the proportion of those with a combat 
deployment are lower comparatively than those without a combat deployment to an OEF or OIF 
battlefield. 
 
Figure 9.  Combat status of OEF/OIF Era Veterans by combat deployment status 
 
Outcome data  
Incident cases of CS A. baumannii and CRAB infections among DoD military personnel during 
the OEF/OIF conflicts indicate that both outcomes were increasing, peaked in 2010 began to fall 
by 2011 and fell dramatically as major combat operations diminished in 2012 when most troops 
were pulled out from Iraq and mission tempo in Afghanistan had been significantly scaled back.  
At which point, cases of both CRAb and A. baumannii are negligible.  
Among DoD personnel who sustained a battle injury while in Operation Enduring Freedom 
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compared to those without a battle injury during the study period (2008-2012) with an incidence 
rate of nearly 10 infections per 1,000 persons compared to those without a battle injury.  
 
Figure 10.  Incident infection cases of A. baumannii and CRAb infections among DoD 
personnel from Iraq and Afghanistan battlefields CY 2008-2015 
 
Incident cases of A. baumannii and CRAb infections across VA involving all eras.  Figure 10 
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Figure 11.  Incident infection cases of A. baumannii and CRAB infections among VA 
patient across all conflict eras  CY2003-2012 
 
Although not as dramatic, in VHA, the observation among OEF/OIF era Veterans was that this 
group had 1.7 times the rate of having a CRAb infection as compared to the general VHA 
population during the study period (2003-2012) as compared to the general VHA population.  
While initially hypothesized to demonstrate a significant relationship between those in the VHA 
population who were OEF/OIF Veterans and had a combat deployment to either battlefield 
theater and develop CRAb infection or have an incident presentation upon enrollment to VHA, 
this group demonstrated a marginal statistical relationship.   
In VHA, incident cases of A. baumannii and CRAB among OEF/OIF veterans follows a similar 
pattern to DoD group where the margin between the proportion of both outcomes is narrow as 
seen in Figure 12. 
 
 
Figure 12.  Incident infection cases of A. baumannii and CRAB infections among OEF/OIF 



























Acinetobacter baumannii & CRAB Cases Among OEF/OIF Era 
Veterans
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Table 4.  Incidence Rates of CRAb and Acinetobacter baumannii (Ab) infections among 
DoD Personnel and VHA Patients Compared to No Exposure 












DoD CRAb Battle Injury 2008-2012 9.831 8.2 [6.938633, 
9.643166] 
< .0001 
DoD Ab Battle Injury 2008-2012 13.108 6.63 [5.790739, 
7.590315] 
< .0001 
DoD CRAb Battle Injury 2008-2011* 11.482 8.26 [7.008497, 
9.740262] 
< .0001 
DoD Ab Battle Injury 2008-2011* 14.991 6.76 [5.89406, 
7.752711] 
< .0001 
VHA CRAb OEF/OIF 
Era 
2003-2012 0.0728 1.7 [1.441253, 
1.885047] 
< .0001 
VHA Ab OEF/OIF 
Era 
2003-2012 0.1494 0.43 [0.3914165, 
0.4684096] 
< .0001 
OEFOIF CRAb Combat 2003-2012 0.049 0.92 [0.5642105, 
1.426329] 
0.7151 
OEFOIF Ab Combat 2003-2012 0.049 0.30 [0.1857809, 
0.449398] 
< .0001 
*By 2012, most DoD personnel had been pulled from Operation Iraqi Freedom (Figures 6 and 10); analysis from 
2008 through 2011 was also considered; 2012 omitted. 
 
 
Results from the linear trend analyses could not be fit in a linear fashion.  This formulation sets 
the trend as the proportion of CRAb amongst A. baumannii isolates.  Due to limited counts, and 
other seemingly inconsistent/missing data, CRAb incidence trends were difficult to ascertain.  
Among OEF/OIF veterans, so few counts were observed that the statistical package could not 
calculate a p-value for the trend.  Limitations to this study may have contributed to the gaps in 







Table 5. Trend Analysis for Proportions of CRAb Infections among DoD Personnel and 
VHA Patients  



















DoD CRAb Battle Injury 2008-2012 ** 61.14 -52.63 0.0178 
DoD CRAb No Battle 
Injury 
2008-2012 ** 47.92 0.64 0.9754 
DoD CRAb Battle Injury 2008-2011* -27.8 76.43 -20.34 0.3736 
DoD CRAb No Battle 
Injury 
2008-2011* -39.8 59.9 45.59 0.0411 
VHA CRAb OEF/OIF 
Era 
2003-2012 -85.5 50.68 -2.69 0.7352 
VHA CRAb Not 
OEF/OIF 
Era 
2003-2012 -84.2 12.55 12.02 < .0001 
OEFOIF CRAb Combat 
Deployment 
2003-2012 ** 74.00 20.28 ** 
OEFOIF CRAb No Combat 
Deployment 
2003-2021 -52.5 34.35 -6.64 0.3790 
*By 2012, most DoD personnel had been pulled from Operation Iraqi Freedom (Figures 6 and 10); analysis from 
2008 through 2011 was also considered; 2012 omitted.  ** Insufficient data to perform calculation or statistical test. 
 
Other Analyses Considered  
Utilization of healthcare is important when determining risk in a hospital population.  Among 
OEF/OIF veterans, the likelihood of this group to utilize VHA healthcare services increased as 
the percentage of a disability for a service-connected injury increased as indicated in Figure 13 
within Appendix A .  In other words, those with the most injuries are seeking VHA services.  
This is represented in.  Service-connected disabled Veteran’s utilization of healthcare services 
and benefits increased from 59% in 2007 to 70% by 2016.  Over 93% of service-connected 




Chapter 5 – Discussion 
 
Summary 
While there were many MDROs to consider amongst returning OEF/OIF veterans, A. baumannii 
was selected for this study because of its ability to specifically impact healthcare settings and the 
speed to which it develops resistance [15, 24, 29, 37].  A. baumannii has impacted combat 
veterans in a variety of injuries sustained during the OEF/OIF conflicts as lifesaving techniques 
and advances in medical evacuation availability have made survival on these battlefields much 
more likely [7, 11].  It was hypothesized that this group of returning combat veterans might be 
reservoirs for A. baumannii and CRAb infections that could be migrated into hospitals and 
medical centers within the Veterans Health Administration and increase infection incidence as a 
result.   
Key results 
We were pleased to see that our findings confirmed higher incidence of CRAb among military 
personnel with battle injuries than those without battle injuries.  Among DoD personnel who 
sustained a battle injury while in Operation Enduring Freedom (OEF) and/or Operation Iraqi 
Freedom (OIF), had 8.1 times the rate of having a CRAb infection compared to those without a 
battle injury during the study period (2008-2012). In VHA, the observation among OEF/OIF era 
Veterans was that this group had 1.7 times the rate of having a CRAb infection as compared to 
the general VHA population during the study period (2003-2012).  Among OEF/OIF era veterans 
in VHA, incidence rates of CRAb among those with and without a previous combat deployment, 
there was no statistically significant relationship.  We remained puzzled as to the low incidence 




Care of the evacuated casualties has also been improved from previous conflicts to the point 
where many soft tissue wounds sustained during combat were no longer infected or even 
colonized once arriving at a Level V tertiary medical center (National Naval Medical Center) in 
the U.S. upon departure from Level IV care at LRMC and others.  Although not a definitive 
study, it represents a snapshot of the complexity of wound management from combat areas [38].  
This may have contributed to the lack of a statistical support between incidence of CRAb among 
OEF/OIF era veterans in VHA that had a combat deployment (exposed) to the OEF/OIF theaters 
and those that did not (not exposed).   
 
Other explanations of low incidence of A. baumannii and CRAb cases in VHA could be that by 
March 2007, the VHA was able to launch a successful comprehensive initiative aimed at 
preventing methicillin-resistant Staphylococcus aureus (MRSA) across the network of 153 
medical centers and hospitals [39]. This was a very robust initiative in that it involved admission 
screenings for MRSA colonization via nasal swab and required contact precautions (gown and 
gloves) for any contact with the patient and their surroundings as well as extensive handwashing 
[40].  This program was able to reduce Staphylococcus aureus infections by 43% and MRSA 
infections by 55% [39].  While strategically aimed at the prevention of MRSA among VHA 
patients, the successful impact this program had on the reduction of incident cases of MRSA may 
have carried over into reducing incidence rates of other MDROs such as CRAb.   Another study 
examining hospital-onset Gram-negative rod (GNR) bacteremia in VHA also noticed that the 
success of the MRSA prevention program had a horizontal effect on their initial research target 
surrounding the impact of GNRs (E. coli, Klebsiella spp., Pseudomonas aeruginosa) in 
bacteremia within VHA [41].  They also discovered because of the MRSA Prevention initiative 
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that there was a sustained reduction in hospital-acquired GNR bacteremia incidence rates by -
42% from January 2003 until December 2013.  Similar observations of lower than normal counts 
were made among GNR subgroup analyses of each bacterial species and susceptibility profiles 
[41] Another recently published study within VHA examining extensively drug-resistant (XDR) 
Acinetobacter baumannii, observed a similar effect among this virulent phenotype [42].  It is not 
uncommon for successful infection prevention programs to have these types of effects.  In the 
civilian non-VHA population, healthcare associated infections among CRAb had decreased from 
58% in 2011 [43] to only 39% from 2015 – 2017 [44]. 
However, this study was able to identify higher incidence rates of CRAb among OEF/OIF era 
veterans as compared to the general VA population as seen in Figures 11 and 12, respectively.  
While this study found that incidence rate ratio of CRAb in VHA at 1.7  among those OEF/OIF 
era veterans compared to the general population at VHA, the study was not able to make a 
significant connection among OEF/OIF era with a combat deployment and those without.   
 
Strengths and Limitations 
This study underscores the interconnected relationship between the Department of Defense (the 
feeding organization) and the Department of Veterans Affairs (the receiving organization) and 
why a strong partnership should exist between these two departments of the US Government.  
The OEF/OIF conflicts, although the most recent, are not the last that the United States Armed 
Forces will be involved in as conditions and threats around the world are in constant flux.  Future 
conflicts and wars may unearth other emerging pathogens that could threaten our ability to 
manage them effectively.  Those risks then have the potential to be vertically transferred from 
the DoD population to the VHA population.  Thus, knowing exactly what they are and what they 
are capable of will equip professionals with the tools they will need to be sentries to protect our 
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nation’s wounded warriors and prevent unnecessary collateral damage among a vulnerable 
population at VHA .   
Limitations of this study included the incompleteness of data within the DAVINCI data source.  
DAVINCI only captured data from 2008 forward, so earlier analysis of the OEF/OIF conflicts 
within the DoD group was not possible.  Although not a strong signal in VHA, a closer look at 
the OEF/OIF conflicts in their earlier stages would indicate the potential of A. baumannii without 
a diluted effect by the time these individuals reach VHA facilities.  Furthermore,  the DAVINCI 
data source captured mostly VA-enrolled patients and we were therefore unable to assess those 
that did not enroll in VA services.  As a result, we were unable to perform an appropriate 
comparative analysis between DoD and VA populations during the early years of the OEF/OIF 
conflicts (2003-2007).  Future studies on this topic should consider using the Joint Theater 
Trauma Registry (JTTR), which is the definitive source for battlefield injuries sustained during 
combat operations for the United States Armed Forces. 
Further limitations are the inconsistent laboratory practices for identification of MDROS within 
VHA.  These inconsistencies among the carbapenem-producing organisms (CPOs) produce 
ambiguity in the surveillance results and subsequent infection control procedures .  Although the 
VHA is a national organization with directives aimed nationwide, many local practices are what 
prevail [8].  
 
Interpretation  
This study underscores the need for cooperation in many areas between the DoD and VA due to 
the upstream-downstream relationship of these two departments.  The first area where 
cooperation is needed is records management.  At the present time, records for military members 
are maintained within DoD and not well-shared with VA.  In April 2020, the joint Health 
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Information Exchange (HIE) launched, which is a major step forward in the exchange of medical 
data, but still a significant distance from ideal.  This can make medical histories challenging for 
VA physicians and other professionals to get an accurate representation of the challenges a 
particular patient may be experiencing if left to incomplete medical records or patient reporting 
only.  However, there is a push to streamline one single record that will follow a military recruit 
from basic training to separation from military service and into VHA as part of the Federal 
Electronic Health Record Modernization Program, which the findings of this report support.  
The second major area of cooperation is the research and development efforts the DoD has 
engaged on with regard to the diagnostics and epidemiology that have been done on the lab 
results of those afflicted with pathogenic microorganisms while in military service, particularly 
the molecular infrastructure that can definitively identify highly problematic pathogens, such as 
the ESKAPE cluster of pathogens that have such a major impacts on healthcare [7, 21, 34]. 
 
Many medical centers throughout the VHA rely upon only culture-based lab data for 
identification, diagnosis and later treatment of infections impacting veteran patients [8].  While 
culture data cannot be replaced entirely, rapid nucleic acid identification is the direction clinical 
labs by and large have adopted in providing accurate diagnostics in healthcare settings.  
Pneumonia for example is one of the leading causes of death in the world. Lower respiratory 
infections are the 4th greatest cause of mortality in the world; responsible for 2.6 million deaths 
globally in 2019  [45]. In the United States alone in 2017, 1.3 million instances occurred where 
pneumonia was listed as the primary diagnosis [46].  Furthermore, this disease has an economic 
impact of ~$10 billion in the United States [47].  Pneumonia is a communicable disease affecting 
all age groups and is characterized by infections of viral and/or bacterial and/or fungal 
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pathogens. This makes the identification of a pneumonia-causing pathogen or even multiple 
pathogens, challenging for providers and further complicates treatment planning for favorable 
clinical outcomes.  While in-vitro culture and Gram staining have been standard practice of 
microbial identification in clinical microbiology since the days of Pasteur in the late 19th century, 
these methods have their limitations.  Cultures, for example, take time 24-48 hours for most 
aerobic organisms and even longer for those anaerobic or more fastidious in nature [48].  
Multiplex real-time quantitative polymerase chain reaction (qPCR) is a molecular diagnostic 
assay that can detect organisms in real-time using nucleic acids which culture may not be able to 
successfully recover.  A major advantage of the syndromic testing of the pneumonia panel is the 
ability to detect polymicrobial infections in which viral-viral infections may be detected or 
bacteria-bacteria, or even if viral-bacterial infections are occurring [49].  One such qPCR 
manufacturer, BioFire® FilmArray® Pneumonia (PN) Panel, will produce a rapid molecular 
analysis report in about 1 hour across 33 different targets from sputum, endotracheal aspirate and 
bronchoalveolar lavage (BAL) clinical samples.  These targets involve 8 common respiratory 
viruses, 15 common pneumonia-causing bacteria, 3 atypical bacteria.  An added value of the PN 
panel is its ability to also detect select antimicrobial resistance genes: Methicillin resistance (x3), 
carbapenemases (x6) and extended spectrum beta-lactamases [49].  This rapid information can 
provide the treating physician with real-time information about the pathogen/s afflicting their 
patients so they can make the most informed decision about an appropriate treatment plan to 
produce the best possible clinical outcome and protect the integrity of the antibiotic stewardship 
plan at a local or national level by not propagating antibiotic resistance by improper broad-




Another molecular technique that will provide the best and most complete information about a 
microbial pathogen for VA epidemiologists, clinical laboratory scientists, pharmacists and 
treating physicians is a technology called whole-genome sequencing (WGS) [9].  WGS is a 
molecular technique that maps out an organism’s entire genome in a single run and is the future 
of medicine at the personal level.  What this allows medical scientists to do is see the full 
potential of the organism at a molecular level and understand the lineage of that organism 
through phylogenetic mapping by comparing the regions of the genome by means of a collection 
of single nucleotide polymorphisms (SNPs).  In one study, A. baumannii isolates at the clonal 
level were able to be identified at a threshold of 2,500 core SNPs, while CRAb outbreak strains 
were identified at a threshold of 2.5 core SNPs [9].   WGS has a great deal of application towards 
ESKAPE pathogens and other MDROs in detecting strain types and investigations into outbreaks 
[9, 21, 50].   A. baumannii strain recognition, has medically important consequences as each 
clonal lineage has different impacts to healthcare settings and their populations [9, 18, 23].      
 
Many of the lab techniques in practice today in VHA only identify some phenotypical expression 
in resistance to any given antimicrobial and only provide a limited picture of what MDROs are 
capable of genotypically.  This gap among identification of MDROs exists in the civilian 
population but has also been underscored in VHA [8, 42].  Thus, there is a great missed 
opportunity at VHA to understand the pathogenic potential and the epidemiological patterns 
these organisms follow and may suggest that CRAb and other MDROs are underreported and 
could be another reason for such low CRAb incidence in VHA [9, 42]. We suggest the VHA 
either develop an in-house central reference laboratory or regional laboratories for high-
throughput WGS or utilize a third-party reference laboratory to acquire such information.  This 
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will help to better identify outbreak strains that are problematic for those in ICUs.  Costs for 
WGS have consistently been a major barrier for integration in clinical laboratories for many 
organizations, however WGS is projected to get cheaper and cheaper as time goes on and 
therefore, VHA should be strategically planning and implementing policies and directives for the 
future of hospital epidemiology, infection prevention, infection control and antibiotic 
stewardship [9, 42]. 
 
Conclusion 
Further studies using molecular data are required across large hospital systems or networks to 
determine if related strains are circulated and transmitted patient-to-patient or patient-to-staff 
member within the network to determine if the results of this study are generalizable.  Awareness 
of the epidemiological impact of newly VA-enrollees from DoD as reservoirs should compel 
VHA leadership to modernize the electronic medical record, modernize current pathogen 
identification and surveillance systems, reconsider local and national drug formularies based off 
what organisms are present or threatening the population, and adjust antibiotic stewardship plans 
accordingly. While this study did not assess treatment outcomes for CRAb, it echoes the 
literature in calling for the development of new antimicrobials against MDROs  [1, 51] in order 
to prevent the troubling prophecies of a post-antibiotic era in which the drugs we as a society 
have relied upon for years will be less and less effective and there are no other treatment options 
remaining.   
MDROs such as A. baumannii, are making decisions for their survival at the molecular level as 
to how they adapt to thrive in their environments, whether that is in nature as a wildtype 
organism or as an opportunistic nosocomial pathogen in a healthcare facility.  Our understanding 
of MDROs, research and development of new drugs/treatments, epidemiologic surveillance, 
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infection prevention practices and currently available treatments of MDRO infections also need 
to be at the molecular level if we as a medical community want to make a significant impact to 





1. Williams, D.L., et al., In vivo efficacy of a unique first-in-class antibiofilm antibiotic for biofilm-
related wound infections caused by Acinetobacter baumannii. Biofilm, 2020. 2: p. 100032. 
2. Belasco, A., Troop Levels in the Afghan and Iraq Wars, FY2001-FY2012: Cost and Other Potential 
Issues, report, July 2, 2009; Washington D.C., U.S. Congress, Editor. 2009, Congressional 
Research Service. 
3. CDC, Antibiotic resistance threats in the United States, 2019. 2019. 
4. Tribble, D.R., et al., Infection-associated clinical outcomes in hospitalized medical evacuees after 
traumatic injury: trauma infectious disease outcome study. J Trauma, 2011. 71(1 Suppl): p. S33-
42. 
5. Tribble, D.R., et al., Epidemiology of Trauma-Related Infections among a Combat Casualty 
Cohort after Initial Hospitalization: The Trauma Infectious Disease Outcomes Study. Surg Infect 
(Larchmt), 2018. 19(5): p. 494-503. 
6. Meyer, W.G., et al., Antimicrobial resistance surveillance in the AFHSC-GEIS network. BMC Public 
Health, 2011. 11 Suppl 2: p. S8. 
7. Scott, P., et al., An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus 
complex infection in the US military health care system associated with military operations in 
Iraq. Clin Infect Dis, 2007. 44(12): p. 1577-84. 
8. Fitzpatrick, M.A., et al., Laboratory practices for identification and reporting of carbapenem-
resistant Enterobacteriaceae in Department of Veterans Affairs facilities. Infect Control Hosp 
Epidemiol, 2019. 40(4): p. 463-466. 
9. Fitzpatrick, M.A., E.A. Ozer, and A.R. Hauser, Utility of Whole-Genome Sequencing in 
Characterizing Acinetobacter Epidemiology and Analyzing Hospital Outbreaks. J Clin Microbiol, 
2016. 54(3): p. 593-612. 
10. Davis, K.A., et al., Multidrug-resistant Acinetobacter extremity infections in soldiers. Emerg Infect 
Dis, 2005. 11(8): p. 1218-24. 
11. Murray, C.K., et al., Infections in combat casualties during Operations Iraqi and Enduring 
Freedom. J Trauma, 2009. 66(4 Suppl): p. S138-44. 
12. Weintrob, A.C., et al., Early Infections Complicating the Care of Combat Casualties from Iraq and 
Afghanistan. Surg Infect (Larchmt), 2018. 19(3): p. 286-297. 
13. Murray, C.K., et al., Recovery of multidrug-resistant bacteria from combat personnel evacuated 
from Iraq and Afghanistan at a single military treatment facility. Mil Med, 2009. 174(6): p. 598-
604. 
14. Hujer, K.M., et al., Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. 
isolates from military and civilian patients treated at the Walter Reed Army Medical Center. 
Antimicrob Agents Chemother, 2006. 50(12): p. 4114-23. 
15. Dijkshoorn, L., A. Nemec, and H. Seifert, An increasing threat in hospitals: multidrug-resistant 
Acinetobacter baumannii. Nat Rev Microbiol, 2007. 5(12): p. 939-51. 
16. Peleg, A.Y., H. Seifert, and D.L. Paterson, Acinetobacter baumannii: emergence of a successful 
pathogen. Clin Microbiol Rev, 2008. 21(3): p. 538-82. 
17. Wong, D., et al., Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century 
of Challenges. Clin Microbiol Rev, 2017. 30(1): p. 409-447. 
18. Harris, A.D., et al., Patient-to-Patient Transmission of Acinetobacter baumannii Gastrointestinal 
Colonization in the Intensive Care Unit. Antimicrob Agents Chemother, 2019. 63(8). 
19. Espinal, P., S. Marti, and J. Vila, Effect of biofilm formation on the survival of Acinetobacter 
baumannii on dry surfaces. J Hosp Infect, 2012. 80(1): p. 56-60. 
38 
 
20. Fournier, P.E. and H. Richet, The epidemiology and control of Acinetobacter baumannii in health 
care facilities. Clin Infect Dis, 2006. 42(5): p. 692-9. 
21. De Oliveira, D.M.P., et al., Antimicrobial Resistance in ESKAPE Pathogens. Clin Microbiol Rev, 
2020. 33(3). 
22. Whitman, T.J., et al., Occupational transmission of Acinetobacter baumannii from a United 
States serviceman wounded in Iraq to a health care worker. Clin Infect Dis, 2008. 47(4): p. 439-
43. 
23. Jaidane, N., et al., Genomic analysis of in vivo acquired resistance to colistin and rifampicin in 
Acinetobacter baumannii. Int J Antimicrob Agents, 2018. 51(2): p. 266-269. 
24. Evans, B.A., A. Hamouda, and S.G. Amyes, The rise of carbapenem-resistant Acinetobacter 
baumannii. Curr Pharm Des, 2013. 19(2): p. 223-38. 
25. Akers, K.S., et al., Biofilms and persistent wound infections in United States military trauma 
patients: a case-control analysis. BMC Infect Dis, 2014. 14: p. 190. 
26. Dallo, S.F. and T. Weitao, Insights into acinetobacter war-wound infections, biofilms, and control. 
Adv Skin Wound Care, 2010. 23(4): p. 169-74. 
27. Vijayakumar, S., I. Biswas, and B. Veeraraghavan, Accurate identification of clinically important 
Acinetobacter spp.: an update. Future Sci OA, 2019. 5(6): p. FSO395. 
28. Taitt, C.R., et al., Antimicrobial resistance determinants in Acinetobacter baumannii isolates 
taken from military treatment facilities. Antimicrob Agents Chemother, 2014. 58(2): p. 767-81. 
29. Cai, B., et al., Prevalence of Carbapenem-Resistant Gram-Negative Infections in the United States 
Predominated by Acinetobacter baumannii and Pseudomonas aeruginosa. Open Forum Infect 
Dis, 2017. 4(3): p. ofx176. 
30. Betancourt, J.A., et al., Obesity and Morbidity Risk in the U.S. Veteran. Healthcare (Basel), 2020. 
8(3). 
31. Liu, Y., et al., Prevalence of and Trends in Diabetes Among Veterans, United States, 2005-2014. 
Prev Chronic Dis, 2017. 14: p. E135. 
32. Fulco, C., et al., Gulf War and health. Consensus study report. 2007, Washington, D.C.: National 
Academy Press. v. <1-8, 10-11>. 
33. Perez, F., et al., Antibiotic resistance determinants in Acinetobacter spp and clinical outcomes in 
patients from a major military treatment facility. Am J Infect Control, 2010. 38(1): p. 63-5. 
34. Huang, X.Z., et al., Genotypic and phenotypic correlations of multidrug-resistant Acinetobacter 
baumannii-A. calcoaceticus complex strains isolated from patients at the National Naval Medical 
Center. J Clin Microbiol, 2010. 48(11): p. 4333-6. 
35. Petersen, K., et al., Diversity and clinical impact of Acinetobacter baumannii colonization and 
infection at a military medical center. J Clin Microbiol, 2011. 49(1): p. 159-66. 
36. VA, 2017 Management Of Infectious Diseases And Infection Prevention And Control Programs, 
N.I.D. Service, Editor. 2017, Veterans Health Administration, Department of Veterans Affairs: 
Washington DC. 
37. Richet, H. and P.E. Fournier, Nosocomial infections caused by Acinetobacter baumannii: a major 
threat worldwide. Infect Control Hosp Epidemiol, 2006. 27(7): p. 645-6. 
38. Sheppard, F.R., et al., The majority of US combat casualty soft-tissue wounds are not infected or 
colonized upon arrival or during treatment at a continental US military medical facility. Am J 
Surg, 2010. 200(4): p. 489-95. 
39. Jones, M., et al., Vital Signs: Trends in Staphylococcus aureus Infections in Veterans Affairs 




40. Evans, M.E., et al., Veterans Affairs methicillin-resistant Staphylococcus aureus prevention 
initiative associated with a sustained reduction in transmissions and health care-associated 
infections. Am J Infect Control, 2013. 41(11): p. 1093-5. 
41. Goto, M., et al., The Effect of a Nationwide Infection Control Program Expansion on Hospital-
Onset Gram-Negative Rod Bacteremia in 130 Veterans Health Administration Medical Centers: 
An Interrupted Time-Series Analysis. Clin Infect Dis, 2016. 63(5): p. 642-650. 
42. Fitzpatrick, M.A., et al., Epidemiology and clinical outcomes associated with extensively drug-
resistant (XDR) Acinetobacter in US Veterans' Affairs (VA) medical centers. Infect Control Hosp 
Epidemiol, 2021. 42(3): p. 305-310. 
43. Weiner, L.M., et al., Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated 
Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers 
for Disease Control and Prevention, 2011-2014. Infect Control Hosp Epidemiol, 2016. 37(11): p. 
1288-1301. 
44. Weiner-Lastinger, L.M., et al., Antimicrobial-resistant pathogens associated with adult 
healthcare-associated infections: Summary of data reported to the National Healthcare Safety 
Network, 2015-2017. Infect Control Hosp Epidemiol, 2020. 41(1): p. 1-18. 
45. WHO, Mortality database [online database]. 2020. 
46. CDC, Pneumonia, U.D.o.H.a.H. Services, Editor. 2020, National Center for Health Statistics: 
FastStats Home page. 
47. Pfuntner, A., L.M. Wier, and C. Steiner, Costs for Hospital Stays in the United States, 2010: 
Statistical Brief #146, in Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. 2006: 
Rockville (MD). 
48. Murray, P.R. and P.R. Murray, Pocket guide to clinical microbiology. 2nd ed. 1998, Washington, 
D.C.: ASM Press. xiv, 359 p. 
49. BioFire, 510(k) substantial equivalence determination summary K180966: FilmArray pneumonia 
panel, U.D.o.H.a.H. Services, Editor. 2018: Washington, DC. 
50. Pendleton, K.M., et al., Rapid Pathogen Identification in Bacterial Pneumonia Using Real-Time 
Metagenomics. Am J Respir Crit Care Med, 2017. 196(12): p. 1610-1612. 
51. Isler, B., et al., New Treatment Options against Carbapenem-Resistant Acinetobacter baumannii 
Infections. Antimicrob Agents Chemother, 2019. 63(1). 
52. VA. U.S. Veterans Eligibility Trends and Statistics. National Center for Veterans Analysis and 






Appendix A:  VHA Health Care Utilization 
 
 
Figure 13 - Service-connected disabled Veteran’s utilization of healthcare services and 
benefits increased from 59% in 2007 to 70% by 2016.  Over 93% of service-connected 
disabled Veterans were enrolled in VHA in 2016 







Figure 14 - The likelihood of Veterans with a service-connected disability pursuing VHA 
health benefits and services increase as the Veteran’s disability rating increases from 0-
100% disabling. 
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then using appropriate data management practices to provide the committee with data analysis to drive 
decisions regarding the mitigation of exposure to Legionella pneumophila bacteria, the disease agent for 
Legionnaire’s disease.  This project was competed at the national level and received the top award for 
its successful planning, implementation, and organizational impact.  The success of the project 
generated a divergence in his administrative career track to one geared more towards more science. He 
would later enroll at Weber State University in Ogden, UT and pursue a second bachelor’s degree in 
microbiology.  Upon completion of this program, he functioned as a Research Microbiologist with the 
University of Utah studying bacterial biofilms and the roles, they play in healthcare impacts and disease 
burden.  To date, two research publications have resulted from his work in the Bone and Joint Research 
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